Search results for: "TG Therapeutics"
2 results found.
1. Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies. | 2014 ASCO Annual Meeting Abstracts
... University of Texas Health Science Center at San Antonio, San Antonio, TX; TG Therapeutics, Inc., New York, NY; Rhizen Pharmaceuticals S.A. ...
2. A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab. | 2014 ASCO Annual Meeting Abstracts
... Athens, GA; Carol G. Simon Cancer Center, Morristown, NJ; TG Therapeutics, Inc., New York, NY Abstract Disclosures Abstract: Background ...
Search powered by Zoom Search Engine